Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT

被引：19
作者：
Pan, Qingqing [1 ,2 ,3 ]
Luo, Yaping [1 ,2 ,3 ]
Cao, Xinxin [2 ,4 ]
Ma, Yanru [1 ,2 ,3 ]
Li, Fang [1 ,2 ,3 ]
机构：
[1] Chinese Acad Med Sci, Dept Nucl Med, Beijing 100730, Peoples R China
[2] Beijing Union Med Coll Hosp, Beijing 100730, Peoples R China
[3] Chinese Acad Med Sci, Beijing Key Lab Mol Targeted Diag & Therapy Nucl, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Dept Hematol, Beijing, Peoples R China
来源：
CLINICAL NUCLEAR MEDICINE | 2018年 / 43卷 / 06期
基金：
中国国家自然科学基金;
关键词：
Ga-68-pentixafor; multiple myeloma; PET; CT; CXCR4; EXPRESSION;
D O I：
10.1097/RLU.0000000000002067
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 60-year-old woman diagnosed with multiple myeloma was referred for 68Ga-pentixafor PET/CT for evaluation of the disease. Diffuse and intense radioactivity throughout the axial and proximal appendicular skeleton was noted on PET/CT images, suggestive of extensive involvement of multiple myeloma. © 2018 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码：462 / 463
页数：2
相关论文
共 8 条
[1]  
Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109
[2]   First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease [J].
Herrmann, Ken ;
Schottelius, Margret ;
Lapa, Constantin ;
Osl, Theresa ;
Poschenrieder, Andreas ;
Haenscheid, Heribert ;
Lueckerath, Katharina ;
Schreder, Martin ;
Bluemel, Christina ;
Knott, Markus ;
Keller, Ulrich ;
Schirbel, Andreas ;
Samnick, Samuel ;
Lassmann, Michael ;
Kropf, Saskia ;
Buck, Andreas K. ;
Einsele, Hermann ;
Wester, Hans-Juergen ;
Knop, Stefan .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) :248-251
[3]   [68Ga] Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F] FDG and laboratory values [J].
Lapa, Constantin ;
Schreder, Martin ;
Schirbel, Andreas ;
Samnick, Samuel ;
Kortuem, Klaus Martin ;
Herrmann, Ken ;
Kropf, Saskia ;
Einsele, Herrmann ;
Buck, Andreas K. ;
Wester, Hans-Juergen ;
Knop, Stefan ;
Lueckerath, Katharina .
THERANOSTICS, 2017, 7 (01) :205-212
[4]   New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma [J].
Mesguich, Charles ;
Zanotti-Fregonara, Paolo ;
Hindie, Elif .
THERANOSTICS, 2016, 6 (02) :287-290
[5]   In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma [J].
Philipp-Abbrederis, Kathrin ;
Herrmann, Ken ;
Knop, Stefan ;
Schottelius, Margret ;
Eiber, Matthias ;
Lueckerath, Katharina ;
Pietschmann, Elke ;
Habringer, Stefan ;
Gerngross, Carlos ;
Franke, Katharina ;
Rudelius, Martina ;
Schirbel, Andreas ;
Lapa, Constantin ;
Schwamborn, Kristina ;
Steidle, Sabine ;
Hartmann, Elena ;
Rosenwald, Andreas ;
Kropf, Saskia ;
Beer, Ambros J. ;
Peschel, Christian ;
Einsele, Hermann ;
Buck, Andreas K. ;
Schwaiger, Markus ;
Goetze, Katharina ;
Wester, Hans-Juergen ;
Keller, Ulrich .
EMBO MOLECULAR MEDICINE, 2015, 7 (04) :477-487
[6]   [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent [J].
Schottelius, Margret ;
Osl, Theresa ;
Poschenrieder, Andreas ;
Hoffmann, Frauke ;
Beykan, Seval ;
Haenscheid, Heribert ;
Schirbel, Andreas ;
Buck, Andreas K. ;
Kropf, Saskia ;
Schwaiger, Markus ;
Keller, Ulrich ;
Lassmann, Michael ;
Wester, Hans-Juergen .
THERANOSTICS, 2017, 7 (09) :2350-2362
[7]   CXCL12 (SDF-1)/CXCR4 Pathway in Cancer [J].
Teicher, Beverly A. ;
Fricker, Simon P. .
CLINICAL CANCER RESEARCH, 2010, 16 (11) :2927-2931
[8]   Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging [J].
Wester, Hans Juergen ;
Keller, Ulrich ;
Schottelius, Margret ;
Beer, Ambros ;
Philipp-Abbrederis, Kathrin ;
Hoffmann, Frauke ;
Simecek, Jakub ;
Gerngross, Carlos ;
Lassmann, Michael ;
Herrmann, Ken ;
Pellegata, Natalia ;
Rudelius, Martina ;
Kessler, Horst ;
Schwaiger, Markus .
THERANOSTICS, 2015, 5 (06) :618-630
1